Mental health care company focusing on accelerating patient access to evidence-based innovation in mental health COMPASS Pathways Plc. (CMPS) signed a memorandum of understanding with the institute of psychiatry, psychology and neuroscience at King’s College London and South London and the Maudsley NHS Foundation Trust to speed psychedelics research and to develop new models of mental health care in the UK.
This partnership will have the three entities collaborating on a multi-year partnership which will reflect their commitment in delivering innovation in mental health care. The partnership aims to include research into COMP360 psilocybin therapy and other novel therapies which are being developed by COMPASS Pathways to treat depression, anorexia and post-traumatic stress disorder (PTSD).
This collaboration will also include training therapists in psychedelics therapies, prototyping digital solutions, generating real world evidence and setting up state-of-art facilities for research and modeling the mental health care clinic of the future.
“We believe this collaboration could accelerate much-needed research that will translate into evidence-based and direct patient care for people who use our services. This is a really exciting prospect and has the potential to change people’s lives for the better,” said the CEO of South London and Maudsley NHS Foundation, David Bradley.